Overview of Pharmaceutical Market Intelligence Providers

Evaluate Ltd (EvaluatePharma) is a UK-based analytics firm (now with a US office) specializing in pharmaceutical commercial intelligence and R&D portfolio analytics. Evaluate is part of Norstella. Citeline and Norstella announced completion of their merger on November 1, 2022; Norstella described the combined organization as a $5 billion pharmaceutical technology company Norstella. Norstella was named to Fast Company's Most Innovative Companies of 2025, ranking 4th among data science companies ^[3]. Founded in the 1990s, Evaluate built its reputation on sales forecasts and consensus data for marketed drugs and pipelines. Its flagship offerings include Evaluate Pharma, which provides consensus sales forecasts and market sizing, and Evaluate Omnium, a predictive risk–return platform for drug assets ^{[1] [4]}. In 2024, Norstella launched NorstellaLinQ, which Norstella describes as an integrated data asset combining real-world data with proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data, powered by AI, LLMs and machine learning ^[5]. Evaluate combines proprietary data (e.g. consensus forecasts from industry analysts, historical sales, clinical trial outcomes) with machine learning. For example, Evaluate stated that Evaluate Omnium uses approximately 6 million data points across 26,000 R&D programs to model each asset's probability of success and commercial value, and reported 4× greater accuracy for predicting which Phase I drugs will reach market versus calculations based on industry benchmark data ^[6].

• Specialization: Commercial forecasting (market sizing, sales consensus), pipeline analytics (clinical and regulatory status of products), portfolio optimization (risk/return of assets) ^{[4] [1]}.

• Services/Data: Offers interactive databases, reports and dashboards. Data sources include regulatory filings, company financials, clinical trial registries, market research, and curated analyst estimates. Methodologies combine statistical modeling (consensus forecast generation) and ML risk models ^[6].

• Clients & Coverage: Evaluate presents its offerings for biopharma, professional-services, and financial-services users, and lists regional forecasts for Japan and Europe. Product coverage and availability should be confirmed for the specific service and market. Evaluate

• Use Cases: Portfolio planning, licensing/deal evaluation, competitive benchmarking, market-entry strategy and investor research. For example, clients use Evaluate to size markets for new drugs, benchmark competitor sales, and assess the value of in-licensing opportunities.

• Strengths: Deep expertise in forecasting (with long-term consensus forecasts to 2030+), integration of sales data and R&D outcomes, and advanced risk modeling (e.g. Omnium's ML approach). Publications (World Preview reports) reinforce its authority. As part of Norstella, Evaluate benefits from cross-platform data integration through NorstellaLinQ, which combines Evaluate's forecasting data with Citeline's clinical trial intelligence, MMIT's payer data, and Panalgo's analytics ^[5].

• Limitations: As a consensus-based service, it may lag real-time events or emerging trial results. It focuses on product- and company-level data rather than patient-level data. Some users note it emphasizes top-line sales and pipeline rather than granular metrics like pricing or patient outcomes.

IQVIA (formed by the 2016 merger of IMS Health and Quintiles) is one of the largest global life sciences data and analytics companies ^[2]. With approximately 93,000 employees in over 100 countries, it offers comprehensive commercial and real-world data for pharmaceuticals. Key data assets include: (a) National Prescription Audit (NPA) – daily US pharmacy dispensing data covering ~93% of outpatient prescriptions ^[7], (b) Xponent – prescriber-level prescription data (93% retail and 77% non-retail US coverage) ^[8], and (c) MIDAS – a global drug sales database consolidating IMS audits into a worldwide market view ^[9]. IQVIA’s offerings also span patient claims/EHR (^[10]), consulting, contract research, and AI-enabled market intelligence.

• Specialization: Commercial analytics (sales, prescribing, market share), real-world evidence, and clinical research services ^[2].

• Services/Data: Provides syndicated data products (prescriptions, doctor visits and hospital data), analytics platforms and consulting solutions. Methodologies include longitudinal patient tracking, statistical projections, and AI-driven forecasting. In 2024, IQVIA launched the IQVIA AI Assistant, which won the PM360 Innovation Award for AI. This conversational tool uses advanced data science to provide rapid, precise answers to complex business questions ^[11]. IQVIA also announced a strategic collaboration with Amazon Web Services (AWS) as its Preferred Agentic Cloud Provider to power next-generation agentic AI for clinical trial automation, medical affairs and analytics ^[12].

• Clients & Coverage: IQVIA serves pharmaceutical and biotech companies, healthcare providers and payers. IQVIA reports approximately 93,000 employees and operations in more than 100 countries IQVIA corporate profile. Transactional-data coverage varies by product and market.

• Use Cases: Sales performance tracking, forecasting demand, segmentation analysis, portfolio optimization, and real-world evidence generation. Commercial teams use IQVIA data to monitor brand performance and prescribing trends; HEOR teams use claims/EHR data for outcomes research; R&D uses its patient recruitment and site feasibility analytics.

• Strengths: Large-scale data assets, including transactional and patient-level datasets, alongside a broad set of clinical, commercial and real-world-evidence services. Its international operations and historical data can be useful for organizations that need coverage across multiple markets.

• Limitations: Because of its scale, customization can be complex. Coverage outside major markets (e.g. low-income countries) is thinner. As a commercial vendor, access often requires large budgets and multi-year contracts.

Clarivate Plc is a UK-based analytics company that acquired several pharma intelligence assets (e.g. Cortellis suite from Thomson Reuters and Decision Resources Group) ^{[13] [14]}. Under its Cortellis Life Sciences Intelligence brand, Clarivate offers a broad portfolio of drug, clinical trial and regulatory databases and analytics. Key components include Cortellis Product Intelligence (global drug pipeline data), Clinical Trials Intelligence (enhanced trial registries), Regulatory Intelligence (global approvals/regulations), Deals Intelligence (licensing/M&A terms), and Competitive Intelligence dashboards ^{[15] [16]}. Clarivate also provides related news and analysis (e.g. Pink Sheet for policy) and patent analytics (Derwent Innovation). In December 2025, Clarivate launched the Cortellis Regulatory Intelligence AI Assistant, offering instant, cited, context-aware answers, multilingual support, rapid document summarization, and draft-versus-final guidance comparison to accelerate regulatory review and decision-making Clarivate.

• Specialization: End-to-end R&D intelligence: drug discovery and preclinical data, clinical trial tracking, regulatory intelligence, product/commercial lifecycle, and transaction analysis. Clarivate also offers pharmacovigilance and safety (Off-X) and epidemiology modules.

• Services/Data: Cortellis databases are built from proprietary curation (analysts manually review thousands of sources) and licensing of public data. For example, Cortellis Competitive Intelligence aggregates all pipeline and competitor data into one platform ^[16]. Deals Intelligence offers comparable deal terms and financials for licensing/M&A ^[16]. Clarivate’s Epidemiology Intelligence (healthbase) and social media databases also inform market access strategies. The Clarivate BI platform allows API access and analytics.

• Clients & Coverage: Clarivate markets Cortellis Clinical Trials Intelligence to clinical-development, business-development, portfolio-strategy and competitive-intelligence teams. Its product pages describe a global clinical-trial landscape and regulatory intelligence across 80+ markets; the available data and geographic scope vary by module. Clarivate Clinical Trials Intelligence Clarivate Regulatory Intelligence

• Use Cases: R&D portfolio planning, competitive landscape analysis, clinical development strategy, licensing negotiations, regulatory strategy, and patent research. For example, teams use Cortellis to scout new targets, track competitor pipelines, and benchmark successful trials.

• Strengths: A broad product suite spanning discovery, clinical development, regulatory intelligence and deal intelligence. The applicable data coverage, history and analyst services should be evaluated by module.

• Limitations: The extensive database can be complex to navigate, and product scope and licensing terms should be assessed module by module. Clarivate reported the divestiture of ScholarOne in November 2024; that transaction alone does not establish the status of other product groups Clarivate.

Citeline is a Norstella business that provides intelligence, data and software for clinical trials, development and regulatory compliance. It was formerly part of Informa’s Pharma Intelligence business before rebranding in 2022. Citeline and Norstella announced completion of their merger on November 1, 2022. Norstella described the combined organization as including Evaluate, MMIT, Panalgo and The Dedham Group Norstella. The Citeline suite includes products from PharmaProjects, TrialTrove and other legacy brands. Citeline publishes Pink Sheet (regulatory news and policy analysis) and EP Vantage (industry commentary); BioWorld is a Clarivate news service.

• Specialization: R&D pipeline and clinical trial tracking, plus regulatory/policy updates. Citeline covers every phase of drug (and device) development and related news, including products like PharmaProjects and TrialTrove; Pink Sheet covers FDA/EMA policy and regulations.

• Services/Data: Data sources are primarily manually-curated by teams of analysts: registry data (ClinicalTrials.gov and global equivalents), company disclosures, scientific literature, regulatory bulletins, and industry news. The content is vetted and validated by human experts. The web platforms allow querying pipelines by disease, company, mechanism, etc. Recent innovations include APIs to integrate Citeline data into client systems. In 2024, Citeline launched SmartSolutions – including Protocol SmartDesign and Investigator SmartSelect – which combine AI, machine learning and LLMs with Trialtrove and Sitetrove data to optimize clinical trial planning and site selection ^[17]. In a December 2025 Norstella hackathon, a Citeline team built a working TrialMatch prototype to help patients find clinical trials suited to their health profiles; Norstella described the work as being in early market validation and architecture planning ^[18].

• Clients & Coverage: Typical users are pharma/biotech R&D and BD teams, consultancies, and investors. Coverage is global and spans all therapeutic areas. Citeline is over 35 years old and covers most drug development data worldwide. Citeline data includes small and large companies, making it useful for both Big Pharma and emerging biotech.

• Use Cases: Competitor and pipeline monitoring, clinical trial design and site feasibility (via site/hospital data), partnership and licensing scouting, safety/regulatory intelligence. For example, companies use Citeline Trialtrove to find experienced trial sites, and Pink Sheet to stay abreast of FDA guidance.

• Strengths: Highly curated R&D information and an integrated offering spanning pipeline, trial and regulatory news. The combination of Citeline and Pink Sheet can give users a broad view of development projects and policy. Norstella says its SmartSolutions products use AI, machine learning, LLMs, and Citeline data assets to support clinical-trial planning and site selection; users should assess performance for their own use case.

• Limitations: Citeline’s core products focus on clinical, development and regulatory intelligence. Commercial forecasting is available elsewhere in Norstella’s portfolio, including through Evaluate, so buyers should confirm the data and product scope required for their use case. Pricing and licensing terms should be assessed directly with the provider.

GlobalData is a UK-based analytics and research company that provides a one-stop intelligence center for the pharmaceutical industry. Its GlobalData Pharmaceuticals platform aggregates “a vast amount of data” on drug development, clinical trials, regulatory affairs and market dynamics worldwide ^[19]. According to a 2024 library announcement, GlobalData’s pharma database includes company profiles (with M&A history) and drug profiles detailing pipelines, trials, regulatory milestones, biomarkers and even social media analytics ^[20]. In addition to its databases, GlobalData publishes market research reports and consulting on pharm/biotech sectors.

• Specialization: Holistic coverage of pharma R&D and market, with additional focus on drug pricing/access. It offers tools for company and product intelligence, as well as forecasting market trends.

• Services/Data: The GlobalData Pharma platform (“Intelligence Center”) includes news, deals database, market/therapy reports, and online databases. Data are compiled from public sources (clinical trial registries, patent filings, news releases) and standardized across geographies ^[19]. It also offers a Pricing and Market Access database for global drug pricing and reimbursement (noted on its site) ^[21].

• Clients & Coverage: Aimed at pharmaceutical companies, manufacturers and suppliers worldwide. The offering is global, with country-specific modules (news, market data) and coverage of major and emerging markets ^[22].

• Use Cases: Trend analysis, competitor benchmarking, licensing/investment decisions. For example, GlobalData is used for identifying emerging markets and therapies, understanding competitor pipelines, and anticipating regulatory changes.

• Strengths: Integrates both broad market data and detailed R&D insights. Its reports and analyst commentary add qualitative context. The unified platform makes it easy to cross-reference company vs. product info.

• Limitations: Although GlobalData was formed in 2016 through the consolidation of established data and analytics providers, some customers may prefer the deep legacy of older databases. Data may be less granular in certain areas compared to specialists (e.g. shorter historical timelines in emerging markets). GlobalData's 2026 industry outlook reports that 52% of respondents were optimistic or very optimistic about the year ahead; it identifies AI, pricing and reimbursement delays, and supply-chain challenges among the trends expected to have the greatest impact ^[23].

AlphaSense is a US-based SaaS platform (founded 2011) that provides an AI-powered search and intelligence workspace for life sciences and other industries. It aggregates "an extensive universe of public and private content" – including SEC filings, earnings call transcripts, analyst reports, patents, news, journals and more – and applies natural language search and AI features to surface insights ^[24]. AlphaSense is not pharma-specific, but offers industry vertical solutions; its Pharma & Biotech module is tailored for healthcare intelligence ^[25]. In October 2025, AlphaSense reported that it had surpassed $500 million in annual recurring revenue (ARR), served more than 6,500 customers (including 88% of the S&P 100), and raised $1.63 billion in total funding AlphaSense press release. The company was named to the 2025 CNBC Disruptor 50 list and acquired Carousel Technologies in October 2025 to expand its AI suite with spreadsheet generation capabilities.

• Specialization: Document-based competitive intelligence. Rather than its own curated data, AlphaSense specializes in fast retrieval of information from published content. In pharma, it is used to “track competitors, monitor clinical trials and disease areas, and keep a pulse on the market landscape” ^[26].

• Services/Data: AlphaSense ingests thousands of sources (equity research, pharma newswires, conference filings, regulatory filings) and uses AI to index concepts and summarize content. It offers alerts and dashboards to follow mentions of companies, drugs or topics. Source types include company reports, press releases, medical journals, trade news (e.g. BioWorld, but not limited to one publication).

• Clients & Coverage: Clients include pharmaceutical and biotech companies, financial institutions, consultancies and government. Coverage is global (multi-language content, with deep US and European focus) since it pulls from international newswires and filings.

• Use Cases: Competitive monitoring, early warning on clinical/regulatory events, trend analysis. For example, a pharma user might set up alerts for competitor trial IDs, FDA announcements or changes in industry sentiment. Investment analysts use it for due diligence on biotech deals.

• Strengths: Very fast search across disparate content; powerful AI filters (e.g. sentiment analysis, concept search). Because it covers both public and private research (paid content from partner publishers), it can access hard-to-find information.

• Limitations: Relies on external published content, so it may miss unpublished data. It provides unstructured information (documents) rather than structured databases, so users must interpret and extract the insights. Coverage quality depends on sources – e.g. less coverage of some Asian markets or non-English sources compared to Western media.

Optum (part of UnitedHealth Group) is a major healthcare data and analytics company, well-known in pharma for its Real-World Data (RWD) assets and insights. Its products include claims/EHR databases (Optum Clinformatics, Optum EHR), and analytical platforms for life sciences. Notably, Optum Enlighten is a “pharma intelligence platform” that uses proprietary data to identify disease prevalence and patient segmentation at hyper-local levels ^[27]. Optum also offers consulting and AI tools (e.g. using Apple Watch data in trials ^[28]).

• Specialization: Real-world evidence (RWE) and analytics. Optum excels at de-identified patient-level data (insurance claims, medical records) covering hundreds of millions of US lives. It translates this into market intelligence (e.g. disease burden, treatment patterns) and outcomes research.

• Services/Data: Optum delivers RWD sets, cohort analysis tools, and bespoke analytic services. Its current Optum Market Clarity Data offering combines de-identified clinical and multi-payer claims data. Optum says the asset includes over 197 million unique patient lives, 20,000+ mapped clinical variables, more than 1 billion prescriptions and data from more than 150 U.S. payers Optum Market Clarity Data. Data sources include insurance claims and EHR data; Optum also offers data-enrichment and analytics support.

• Clients & Coverage: Primarily US-focused healthcare and pharma companies. Optum reports that Market Clarity Data includes over 197 million unique patient lives from more than 150 U.S. payers; it is a large US real-world-data asset rather than coverage of nearly all insured people. Available data and services should be confirmed for the intended use.

• Use Cases: Disease epidemiology, market segmentation, clinical trial feasibility, HEOR (health economics/outcomes research). For instance, pharma R&D teams use Optum to identify patient cohorts for studies, while commercial teams use it to track market share and adherence trends. Its data also informs value-based contract development.

• Strengths: Optum describes Market Clarity Data as a linked, de-identified clinical and multi-payer claims asset with historical depth, mapped clinical variables and prescription data. Its linkage of clinical and claims data may be useful for organizations whose analysis requires those data types.

• Limitations: Historically US-centric. Access is typically via enterprise license. Some data (e.g. payer-specific or uninsured populations) may be limited.

Cerner Enviza (formerly known as Kantar Health) was a provider of healthcare research, market access and real-world data solutions, combining Kantar's traditional life sciences market research and panel expertise with Cerner's clinical data portfolio ^[29]. Following Oracle's $28.3 billion acquisition of Cerner (closed June 2022), Cerner Enviza is now Oracle Life Sciences. Oracle has since launched a next-generation EHR system built from the ground up on Oracle Cloud Infrastructure with AI and voice capabilities, with ambulatory care available in 2025 and acute care functionality planned for 2026 ^[30]. The combined entity continues to offer patient journey analytics, brand health tracking, and custom primary research alongside RWD access.

• Specialization: Healthcare research data, market research and real-world-data analytics for life sciences. The current Oracle Life Sciences offering includes patient-centric data, insights and consulting; Kantar Health and Cerner Enviza are predecessor names.

• Services/Data: Offers syndicated research (e.g. brand profiles, patient journey studies), custom primary research, and RWE studies. It leverages Cerner’s EHR network (~100m patients) to provide disease analytics. The combined approach “leverages a diverse network of providers and data, expert research capabilities and analytics” ^[31].

• Clients & Coverage: Global life sciences companies and health agencies. Cerner Enviza’s expertise spans oncology, rare diseases, and broad therapeutic areas. Its syndicated studies often cover major markets worldwide.

• Use Cases: Launch strategy (market segmentation, forecasting), ongoing brand support (market share modeling), health economics (cost studies), and patient experience research. For example, they conduct “voice of patient” studies to guide drug development or gauge access barriers.

• Strengths: Mixed-methods approach (qualitative + quantitative), with strong analytics. ISO-certified research processes. The combination of survey data with actual clinical records provides richer insights.

• Limitations: Compared to database firms, much relies on commissioned studies which are time- and resource-intensive. Panels/surveys can suffer from response bias. Access to detailed data often requires custom engagement (less “on-demand” than subscription platforms).

BioCentury is a US-based biotech news and data company, and BCIQ is its drug development database launched in 2021. BCIQ (BioCentury Insight Question) is designed for the biotech investment and business development community. It aggregates data on biotech company pipelines, deals, financing and clinical programs, curated by BioCentury’s editorial and data team ^[32].

• Specialization: Biotech R&D financing and deal intelligence. BCIQ focuses on emerging companies and financing rounds, venture-backed projects, and strategic partnerships. It emphasizes data to “support financing, investing and dealmaking activities” ^[32].

• Services/Data: The platform provides four fully integrated modules: Companies (thousands of public and private company profiles, including a repository of private company data unavailable elsewhere), Financial (data on over $1 trillion in public and private financings), Deals (profiles on M&A, licenses, partnerships, grants and asset purchases), and Products (pipeline analysis by company, disease category and molecular target). It was built on BioCentury's decades of industry publications and proprietary data collection ^[33].

• Clients & Coverage: Primarily biotech and life science investors, venture capital, corporate BD teams, and analysts. Coverage is global but concentrates on companies notable to the investment community (often US/Western biotech).

• Use Cases: Identifying investment targets, benchmarking comparable transactions, monitoring competitor venture funding, and conducting due diligence. Users leverage BCIQ to find comparable deals (e.g. what deal terms a similar asset received) or to track pipeline exits/launches.

• Strengths: A focused offering for biotech financing and deal intelligence, with curated company, financing, deal and product modules BioCentury BCIQ.

• Limitations: Less useful for large-scale commercial sales data or broad patient metrics. Primarily early-stage; coverage of big pharma late-stage assets is limited compared to others. Users must already care about capital markets dynamics to gain value.

Symphony Health is a US healthcare data and analytics company owned by HealthVerity. On May 8, 2026, ICON completed the disposition of Symphony Health Solutions Corporation; HealthVerity's merger subsidiary merged into Symphony, making it a wholly owned HealthVerity subsidiary ICON's SEC filing.

• Specialization: US-focused patient-journey analytics. Symphony combines pharmacy, claims, provider and OTC data to support analyses of treatment patterns and outcomes.

• Services/Data: Offers de-identified patient-level data (including pharmacies, doctors, hospitals, claims) and data linkages (3/4 of patients with Rx linked to diagnoses ^[34]). Its tools allow cross-channel views: e.g. tracking a patient from a hospital stay through medication refills. Data can be delivered via APIs or analytic platforms. Recent innovations include PatientSourceDUO, which combines the longitudinality and breadth of open claims with the patient-level precision and depth of closed claims for a singular dataset spanning the product lifecycle. Symphony also continues to enhance its Metys platform for precise national market analysis ^[35].

• Clients & Coverage: Life sciences companies, healthcare payers and research organizations use Symphony’s US-focused data services. Coverage, history and available channels depend on the licensed dataset and intended use.

• Use Cases: Market access and launch analytics, patient journey mapping, adherence studies, and sales/marketing effectiveness. For example, pharma marketers use Symphony to identify where prescribing drops off and to segment high-value patients, while R&D uses it to assess prevalence of a rare disease.

• Strengths: Multi-channel US data can support longitudinal patient-journey, epidemiologic and commercial analyses, such as cohort identification and measurement of market uptake. Users should evaluate the applicable dataset’s provenance, linkage methods and fitness for the intended analysis.

• Limitations: Geographically limited to the US; international data are not part of this portfolio. As with other RWD firms, it can be costly and requires expertise to analyze. Its availability and product roadmap are now managed within HealthVerity rather than ICON ICON's SEC filing.

Beyond the firms above, several other players offer specialized intelligence: for example, DelveInsight (India-based, pharmaceutical market research and reports), Frost & Sullivan (global market research), Transparency Market Research, and Flatiron Health (a Roche subsidiary specializing in oncology RWD, which in October 2025 unveiled LLM-extracted real-world progression data at unprecedented scale and the VALID Framework for AI data quality in oncology research ^[36]). There are also niche services like HealthCore (real-world evidence), Cytel (trial design software with analytics), and consultancies such as McKinsey and Deloitte, which offer life sciences analysis. The companies profiled above are a representative selection, not a ranking of providers by market share or industry adoption.

Each provider brings different strengths – from Evaluate’s forecasting capabilities to IQVIA’s commercial-data and analytics offerings – so decision-makers may use multiple sources. Collectively, these market intelligence firms enable pharmaceutical companies to forecast demand, allocate R&D resources, benchmark competitors, plan clinical trials, set pricing strategies and comply with regulations. Users must weigh each provider’s coverage, data freshness, and methodology: for instance, proprietary forecast models (Evaluate) versus real-world data (Optum) or curated news (AlphaSense). The table below (Table 1) summarizes key aspects of these providers:

Table 1. Overview of Representative Pharmaceutical Market Intelligence Providers

Provider	Specialties	Data Sources & Services	Coverage	Example Clients/Use Cases
Evaluate Ltd (Norstella)	Commercial forecasts; R&D pipeline; portfolio analytics; NorstellaLinQ [37]	Consensus forecasts, sales data, R&D data, ML risk models, integrated RWD via NorstellaLinQ	Global; coverage varies by product	Portfolio planning, licensing analysis
IQVIA	Sales analytics; market share; prescriptions; RWE; AI Assistant [38]	Prescription audits (NPA, Xponent), physician surveys, claims/EHR, AI-powered forecasting tools	Global (100+ countries, approximately 93,000 employees)	Brand performance tracking, HEOR studies
Clarivate (Cortellis, DRG)	Pipeline/Clinical trial tracking; regulatory AI assistant; deal analytics [39]	Curated trial registries, regulatory filings, news, deals, safety databases, Regulatory AI Assistant	Global	Drug development strategy; deal benchmarking
Citeline (Norstella)	Pipeline & trial data; regulatory news (Pink Sheet); SmartSolutions AI [40]	Manually-curated databases (Trialtrove, PharmaProjects), AI-powered SmartSolutions, analyst commentary	Global	Clinical trial planning; site selection; regulatory compliance
GlobalData Pharma	Company & drug profiles; market trends; pricing/access data	Integrated news & market databases, country reports, pricing database	Global (incl. emerging markets)	Market sizing; trend analysis; competitor R&D
AlphaSense	Competitive intelligence and AI-powered search AlphaSense Pharma & Biotech	AI-powered search across filings, transcripts, journals and news; AlphaSense reported 6,500+ customers in October 2025 AlphaSense press release	Global (multi-language)	Competitor news monitoring; investment research
Optum	Real-world patient analytics; disease prevalence (Optum Enlighten) Optum Life Sciences	US claims/EHR databases and patient panels; Market Clarity Data links de-identified clinical and multi-payer claims data Optum Market Clarity Data	Primarily US	Market segmentation; clinical trial feasibility
Oracle Life Sciences (ex-Cerner Enviza/Kantar)	Market research; patient/physician surveys; RWD analytics; Oracle Cloud AI [41]	Syndicated studies, custom surveys, EHR/claims data, AI-powered EHR	Global (strong in US, EU, Asia)	Launch strategy; patient journey analysis
BioCentury BCIQ	Biotech financing/deal intelligence [32]	Curated data on funding rounds, deals, pipeline metrics	Global (biotech focus)	VC/investment research; BD deal scouting
Symphony Health (HealthVerity)	Multi-channel patient data; US prescription & diagnosis data; PatientSourceDUO ICON's SEC filing	Linked open+closed claims, pharmacy and provider records (US); Metys platform	US market	Epidemiology; channel analytics; adherence studies

Sources: Company websites and industry reports as cited above ^{[42] [43] [2] [44]}. Last updated July 2026.